{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:29:20Z","timestamp":1790087360669,"version":"4.0.1"},"reference-count":141,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":1400,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"TIMING Project"},{"name":"Ricerca di Ateneo"},{"name":"Regione Campania CISI-Lab"},{"name":"CR\u00c8ME Project"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1136\/esmoopen-2017-000247","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T20:10:11Z","timestamp":1509048611000},"page":"e000247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":207,"title":["Cardiotoxicity of immune checkpoint inhibitors"],"prefix":"10.1016","volume":"2","author":[{"given":"Gilda","family":"Varricchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Galdiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Marone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gjada","family":"Criscuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Triassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Bonaduce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Marone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2017-000247_bb0010","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1136\/esmoopen-2017-000247_bb0015","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002843","article-title":"Cancer therapy-related cardiac dysfunction and heart failure: part 2: prevention, treatment, guidelines, and future directions","volume":"9","author":"Hamo","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1136\/esmoopen-2017-000247_bb0020","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1136\/esmoopen-2017-000247_bb0025","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/eurjhf\/hft008","article-title":"The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors","volume":"15","author":"Tocchetti","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1136\/esmoopen-2017-000247_bb0030","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1136\/esmoopen-2017-000247_bb0035","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0040","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"key":"10.1136\/esmoopen-2017-000247_bb0045","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1172\/JCI84236","article-title":"Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey clinical medical research award","volume":"125","author":"Hurst","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1136\/esmoopen-2017-000247_bb0050","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0055","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2017-000247_bb0060","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2017-000247_bb0065","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2017-000247_bb0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0075","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0080","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 Blockade with pembrolizumab in advanced merkel-cell Carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0085","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2017-000247_bb0090","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2017-000247_bb0095","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0100","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0105","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2017-000247_bb0110","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","author":"Badros","year":"2017","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2017-000247_bb0115","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2017-000247_bb0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nri3790","article-title":"Clinical blockade of PD1 and LAG3-potential mechanisms of action","volume":"15","author":"Nguyen","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1136\/esmoopen-2017-000247_bb0130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1136\/esmoopen-2017-000247_bb0135","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fimmu.2015.00418","article-title":"Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators","volume":"6","author":"Le Mercier","year":"2015","journal-title":"Front Immunol"},{"key":"10.1136\/esmoopen-2017-000247_bb0140","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1136\/esmoopen-2017-000247_bb0145","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","article-title":"PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Goodman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","article-title":"Ipilimumab in patients with cancer and the management of dermatologic adverse events","volume":"71","author":"Lacouture","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/esmoopen-2017-000247_bb0155","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1136\/esmoopen-2017-000247_bb0160","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature","volume":"28","author":"Spain","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0165","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2017-000247_bb0170","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"10.1136\/esmoopen-2017-000247_bb0175","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0180","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0185","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0190","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0195","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","article-title":"Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart","volume":"116","author":"Grabie","year":"2007","journal-title":"Circulation"},{"key":"10.1136\/esmoopen-2017-000247_bb0200","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.4049\/jimmunol.181.4.2513","article-title":"Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice","volume":"181","author":"Lucas","year":"2008","journal-title":"J Immunol"},{"key":"10.1136\/esmoopen-2017-000247_bb0205","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/intimm\/dxq026","article-title":"PD-1 deficiency results in the development of fatal myocarditis in MRL mice","volume":"22","author":"Wang","year":"2010","journal-title":"Int Immunol"},{"key":"10.1136\/esmoopen-2017-000247_bb0210","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","article-title":"PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis","volume":"188","author":"Tarrio","year":"2012","journal-title":"J Immunol"},{"key":"10.1136\/esmoopen-2017-000247_bb0215","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.lungcan.2016.06.025","article-title":"Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung","volume":"99","author":"Semper","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1136\/esmoopen-2017-000247_bb0220","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003514","article-title":"Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab","volume":"9","author":"Tadokoro","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1136\/esmoopen-2017-000247_bb0225","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40425-015-0048-2","article-title":"Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome","volume":"3","author":"Geisler","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1136\/esmoopen-2017-000247_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1136\/esmoopen-2017-000247_bb0235","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI35180","article-title":"The anticancer immune response: indispensable for therapeutic success?","volume":"118","author":"Zitvogel","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1136\/esmoopen-2017-000247_bb0240","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrclinonc.2016.144","article-title":"Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape","volume":"14","author":"Mohme","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0245","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin Ther"},{"key":"10.1136\/esmoopen-2017-000247_bb0250","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1136\/esmoopen-2017-000247_bb0255","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/0952-7915(95)80077-8","article-title":"Manipulation of costimulatory signals to enhance antitumor T-cell responses","volume":"7","author":"Allison","year":"1995","journal-title":"Curr Opin Immunol"},{"key":"10.1136\/esmoopen-2017-000247_bb0260","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1136\/esmoopen-2017-000247_bb0265","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1136\/esmoopen-2017-000247_bb0270","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1073\/pnas.96.1.185","article-title":"A two-step, two-signal model for the primary activation of precursor helper T cells","volume":"96","author":"Bretscher","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/esmoopen-2017-000247_bb0275","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"10.1136\/esmoopen-2017-000247_bb0280","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"10.1136\/esmoopen-2017-000247_bb0285","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily-CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2017-000247_bb0290","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","article-title":"CTLA-4 is a second receptor for the B cell activation antigen B7","volume":"174","author":"Linsley","year":"1991","journal-title":"J Exp Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0295","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.4049\/jimmunol.136.9.3282","article-title":"A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes","volume":"136","author":"Martin","year":"1986","journal-title":"J Immunol"},{"key":"10.1136\/esmoopen-2017-000247_bb0300","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1126\/science.7694361","article-title":"Identification of an alternative CTLA-4 ligand costimulatory for T cell activation","volume":"262","author":"Hathcock","year":"1993","journal-title":"Science"},{"key":"10.1136\/esmoopen-2017-000247_bb0305","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1126\/science.7694363","article-title":"Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation","volume":"262","author":"Freeman","year":"1993","journal-title":"Science"},{"key":"10.1136\/esmoopen-2017-000247_bb0310","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/366076a0","article-title":"B70 antigen is a second ligand for CTLA-4 and CD28","volume":"366","author":"Azuma","year":"1993","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2017-000247_bb0315","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1073\/pnas.87.13.5031","article-title":"T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7\/BB-1","volume":"87","author":"Linsley","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/esmoopen-2017-000247_bb0320","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"10.1136\/esmoopen-2017-000247_bb0325","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J Exp Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0330","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1136\/esmoopen-2017-000247_bb0335","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0340","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/imr.12524","article-title":"New checkpoints in cancer immunotherapy","volume":"276","author":"Ni","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1136\/esmoopen-2017-000247_bb0345","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0350","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"10.1136\/esmoopen-2017-000247_bb0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124059","article-title":"Upregulation of programmed death-1 and Its ligand in cardiac injury models: interaction with GADD153","volume":"10","author":"Baban","year":"2015","journal-title":"PLoS One"},{"key":"10.1136\/esmoopen-2017-000247_bb0360","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2017-000247_bb0365","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J Exp Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0370","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett"},{"key":"10.1136\/esmoopen-2017-000247_bb0375","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1136\/esmoopen-2017-000247_bb0380","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nm0902-1039c","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0385","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1136\/esmoopen-2017-000247_bb0390","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2007-11-123141","article-title":"B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells","volume":"111","author":"Azuma","year":"2008","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2017-000247_bb0395","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdv615","article-title":"Regulation of PD-L1: a novel role of pro-survival signalling in cancer","volume":"27","author":"Chen","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0400","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1136\/esmoopen-2017-000247_bb0405","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","article-title":"PD-1 blockade expands intratumoral memory T cells","volume":"4","author":"Ribas","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1136\/esmoopen-2017-000247_bb0410","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0415","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0420","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0425","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0430","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2017-000247_bb0435","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0440","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0445","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMe1705692","article-title":"Cancer immunotherapy trials not immune from imprecise selection of patients","volume":"376","author":"Garon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0450","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0455","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0460","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/nm.4200","article-title":"Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses","volume":"22","author":"Moynihan","year":"2016","journal-title":"Nat Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0465","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23849","article-title":"TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer","volume":"2","author":"Sakuishi","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1136\/esmoopen-2017-000247_bb0470","article-title":"Tim-3 expression defines regulatory T cells in human tumors","volume":"8","author":"Yan","year":"2013","journal-title":"PLoS One"},{"key":"10.1136\/esmoopen-2017-000247_bb0475","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"10.1136\/esmoopen-2017-000247_bb0480","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nm.3179","article-title":"Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells","volume":"19","author":"Gagliani","year":"2013","journal-title":"Nat Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0485","doi-asserted-by":"crossref","first-page":"13974","DOI":"10.1073\/pnas.0906872106","article-title":"CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2","volume":"106","author":"Okamura","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/esmoopen-2017-000247_bb0490","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2017-000247_bb0495","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/esmoopen-2017-000247_bb0500","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1136\/esmoopen-2017-000247_bb0505","doi-asserted-by":"crossref","first-page":"17858","DOI":"10.1073\/pnas.0903474106","article-title":"The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity","volume":"106","author":"Stanietsky","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/esmoopen-2017-000247_bb0510","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1136\/esmoopen-2017-000247_bb0515","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/ni944","article-title":"BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1","volume":"4","author":"Watanabe","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1136\/esmoopen-2017-000247_bb0520","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.4049\/jimmunol.172.10.5931","article-title":"An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection","volume":"172","author":"Han","year":"2004","journal-title":"J Immunol"},{"key":"10.1136\/esmoopen-2017-000247_bb0525","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/mt.2011.88","article-title":"Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice","volume":"19","author":"Lasaro","year":"2011","journal-title":"Mol Ther"},{"key":"10.1136\/esmoopen-2017-000247_bb0530","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA is an immune checkpoint molecule for human T cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2017-000247_bb0535","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-13-1506","article-title":"VISTA Regulates the development of protective antitumor immunity","volume":"74","author":"Le Mercier","year":"2014","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2017-000247_bb0540","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrclinonc.2013.245","article-title":"Mitigating the toxic effects of anticancer immunotherapy","volume":"11","author":"Gangadhar","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0545","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2017-000247_bb0550","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0555","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0560","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0565","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1136\/esmoopen-2017-000247_bb0570","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J Exp Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0575","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1136\/esmoopen-2017-000247_bb0580","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.18632\/oncotarget.13315","article-title":"Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials","volume":"8","author":"Costa","year":"2017","journal-title":"Oncotarget"},{"key":"10.1136\/esmoopen-2017-000247_bb0585","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0590","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0595","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11886-017-0835-0","article-title":"Cardiovascular toxicities associated with cancer immunotherapies","volume":"19","author":"Wang","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"10.1136\/esmoopen-2017-000247_bb0600","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2017-000247_bb0605","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11886-017-0846-x","article-title":"Cardiac complications of cancer therapy: pathophysiology, identification, prevention, treatment, and future directions","volume":"19","author":"Jain","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"10.1136\/esmoopen-2017-000247_bb0610","article-title":"From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular Toxicity: a translational overview","author":"Tocchetti","year":"2017","journal-title":"Antioxid Redox Signal"},{"key":"10.1136\/esmoopen-2017-000247_bb0615","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"10.1136\/esmoopen-2017-000247_bb0620","doi-asserted-by":"crossref","first-page":"e1925","DOI":"10.1097\/MJT.0000000000000430","article-title":"Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma","volume":"23","author":"Roth","year":"2016","journal-title":"Am J Ther"},{"key":"10.1136\/esmoopen-2017-000247_bb0625","first-page":"1","article-title":"Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication","volume":"2015","author":"Yun","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0630","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"L\u00e4ubli","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1136\/esmoopen-2017-000247_bb0635","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003514","article-title":"Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab","volume":"9","author":"Tadokoro","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1136\/esmoopen-2017-000247_bb0640","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-216228","article-title":"Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer","volume":"2016","author":"Gibson","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1136\/esmoopen-2017-000247_bb0645","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-016-0117-1","article-title":"Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study","volume":"4","author":"Koelzer","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1136\/esmoopen-2017-000247_bb0650","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"10.1136\/esmoopen-2017-000247_bb0655","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1080\/14779072.2016.1239528","article-title":"Chemotherapy-induced cardiotoxicity: importance of early detection","volume":"14","author":"Cardinale","year":"2016","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1136\/esmoopen-2017-000247_bb0660","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMra0800028","article-title":"Myocarditis","volume":"360","author":"Cooper","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000247_bb0665","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0670","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2016.2238","article-title":"Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options","volume":"2","author":"Khan","year":"2016","journal-title":"JAMA Oncol"},{"issue":"Suppl","key":"10.1136\/esmoopen-2017-000247_bb0675","first-page":"abstr 9059","article-title":"Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy","volume":"33","author":"Prashanth","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1136\/esmoopen-2017-000247_bb0680","first-page":"abstr 9019","article-title":"Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"33","author":"Douglas","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0685","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/jnci\/djv414","article-title":"Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives","volume":"108","author":"Atkins","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/esmoopen-2017-000247_bb0690","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","article-title":"Combination cancer immunotherapies tailored to the tumour microenvironment","volume":"13","author":"Smyth","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000247_bb0695","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/infdis\/jix191","article-title":"Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy","volume":"215","author":"Gay","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1136\/esmoopen-2017-000247_bb0700","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur J Immunol"},{"key":"10.1136\/esmoopen-2017-000247_bb0705","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"key":"10.1136\/esmoopen-2017-000247_bb0710","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920324042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920324042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2017-000247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:19:42Z","timestamp":1761855582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920324042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":141,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"alternative-id":["S2059702920324042"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2017-000247","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiotoxicity of immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2017-000247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000247"}}